Meta-analysis of differences in PLMAI between rotigotine and placebo-treated groups.

Meta-analysis of differences in PLMAI between rotigotine and placebo-treated groups.</p

The efficacy and tolerability of rotigotine on patients with periodic limb movement in sleep: A systematic review and meta-analysis

<div><p>Objective</p><p>There is still no consensus on the treatment for periodic limb movement in sleep (PLMS). This study aimed to determine the efficacy and tolerability of rotigotine in patients suffering from PLMS.</p><p>Methods</p><p>Publications listed in PubMed, ScienceDirect, The Cochrane Library, and ClinicalTrials.gov were reviewed to assess the efficacy of rotigotine on PLMS. Analyses of PLMS frequency before and after rotigotine treatments (pre- and post-intervention studies) and PLMS frequency between placebo and rotigotine treatments (placebo-controlled trial studies) were included in our study. A systematic review and meta-analysis was conducted.</p><p>Results</p><p>Five publications involving 197 participants were included in this study. Among these articles, pre- and post-intervention data involving 55 participants were available from three articles, while placebo-controlled trial data from 107 participants receiving rotigotine and 70 participants receiving a placebo were available from an additional three articles. In the pre- and post-intervention studies, the periodic limb movement index was significantly decreased after therapy with rotigotine with a difference in means of −5.866/h (95% CI, −10.570 to −1.162, <i>p</i> = 0.015). In comparison with the placebo, the use of rotigotine significantly lowered the periodic limb movement index, with a difference in means of −32.105/h (95% CI, −42.539 to −21.671, <i>p</i> < 0.001), reduced the PLMS with arousal index, with a difference in means of −7.160/h (95% CI, −9.310 to −5.010, <i>p</i> < 0.001), and increased the withdrawal rate, with an odds ratio of 3.421 (95% CI, 1.230 to 9.512, <i>p</i> = 0.018).</p><p>Conclusions</p><p>This meta-analysis revealed the considerable efficacy of rotigotine in alleviating the frequency of PLMS. However, the high withdrawal rate should be taken into account.</p></div

Flowchart of the selection strategy for meta-analysis according to PRISMA guidelines.

Flowchart of the selection strategy for meta-analysis according to PRISMA guidelines.</p

Additional file 1 of Defining cognitive and functional profiles in schizophrenia and affective disorders

Additional file 1: Table S1. Relationships between cognitive function, psychopathology and antipsychotic agents among patients with schizophrenia (n = 63)

Meta-analysis of changes in PLMI after rotigotine treatment.

<p>Meta-analysis of changes in PLMI after rotigotine treatment.</p

Summary of characteristics of the studies included in the meta-analysis.

<p>Summary of characteristics of the studies included in the meta-analysis.</p

Meta-analysis of the withdrawal rate of the rotigotine and placebo-treated groups.

<p>Meta-analysis of the withdrawal rate of the rotigotine and placebo-treated groups.</p

Meta-analysis of differences in PLMI between rotigotine and placebo treatments.

<p>Meta-analysis of differences in PLMI between rotigotine and placebo treatments.</p

BST-1 as a serum protein biomarker involved in neutrophil infiltration in schizophrenia

Schizophrenia is a serious mental illness. The serum protein biomarkers of schizophrenia were explored using isobaric tags for relative and absolute quantitation (iTRAQ) technology. The underlying function of the identified protein biomarker was also investigated. We first collected serum samples from 12 schizophrenia patients and 12 healthy control (HC) subjects, followed by global screening with iTRAQ and tandem mass spectrometry (LC-MS/MS). In total, 691 serum proteins were detected and eight proteins, including ZYX, OSCAR, TPM4, SDPR, BST1, ARGHDB, ITIH5 and SH3BGRL3, were selected for further specific validation with enzyme-linked immunosorbent assay (ELISA) on the serum samples from 52 schizophrenia patients and 50 HC subjects. Schizophrenia patients had significantly lower serum level of BST1 and higher ITIH5 level than the HC subjects did. Using the levels of BST1, ITIH5 and OSCAR combined with machine learning algorithm, we developed a prediction model of schizophrenia with an auROC value 0.78. Moreover, in vitro cell assay confirmed that BST1 significantly repressed neutrophil infiltration through endothelial layer, highlighted the anti-inflammation nature of BST1. Four novel protein markers (BST1, ITIH5, SDPR, and OSCAR) of schizophrenia were identified, and BST-1 could serve as a serum protein biomarker involved in neutrophil infiltration in schizophrenia.</p

Additional file 1 of Assessing the quality of electronic medical records as a platform for resident education

Additional file 1: Supplemental file A. Note template 1. For intensive care unit patients. B. Note template 2. For intensive care unit patients. C. Note template for endocrinology patients